atezolizumab
roche
['dante', 'esophageal']
#asco22 dante randomised phase 2 trial shows 9% increase (15&gt;23%) in pcr rate when atezelizumab added to flot in early stage gastro-oesophageal cancer. very promising! hopefully survival data from dante and ph3 trials of other periop io combos becomes available soon.
Medical Oncologist and Clinician Scientist working on GI Cancer Genomics/Cancer Evolution, Immunotherapies and Biomarkers